Background: Bovine milk-based fortifiers (BMBF) have been standard of care for nutrient fortification of feeds for very low birth weight (VLBW) infants, however, there is increasing use of human milk-based fortifiers (HMBF) in neonatal care despite additional costs and limited supporting data. No randomized clinical trial has followed infants fed these fortifiers after initial hospitalization.
Introduction
Maternal milk is recognized as the best source of nutrition for all infants, particularly those born at a very low birth weight (VLBW, <1500 g) (1) (2) (3) (4) (5) . In the absence of sufficient maternal milk to meet infant needs, feeding pasteurized donor human milk (donor milk) rather than for-mula reduces risk of necrotizing enterocolitis (NEC) without any evidence of long-term effects on survival, growth, or neurodevelopment (6, 7, 8) .
Due to elevated nutritional needs of infants born at a VLBW, additional nutrient fortification is required to support growth and development (9) . Bovine milk-based fortifiers (BMBF) have been the standard of care for VLBW infants; however, human milk-based fortifiers (HMBF) are increasingly used in neonatal intensive care units at substantial additional financial cost. Earlier trials that compared HMBF and BMBF found that infants fed maternal milk or donor milk fortified with HMBF had lower rates of NEC and improved feeding tolerance relative to infants fed maternal milk fortified with BMBF and supplemented with formula as necessary (10) (11) (12) . Although promising, these trials compared infants fed exclusively human milk products to those who received bovine products as formula and BMBF, so it was unclear whether the absence of BMBF, infant formula, or a combination of the 2 factors explained the better outcomes in the HMBF group. In addition, these trials do not reflect the current standard of care in North America, where it is recommended that VLBW infants be fed maternal milk first with donor milk, and not formula, as a supplement (13) (14) (15) . To address these issues, our group conducted a randomized clinical trial that compared the use of HMBF and BMBF in VLBW infants fed human milk diets without any formula (16) . In contrast to the earlier findings, our trial identified no differences in feeding tolerance or rates of Bell Stage ≥II NEC between the groups.
Follow-up comparing subsequent neurodevelopment in infants fed HMBF or BMBF is important for several reasons. Feeding infants maternal milk rather than bovine milk-derived formula is associated with improved performance on intelligence and cognitive tests in childhood and adolescence, even after adjusting for maternal education or socioeconomic status (5, 17) . These differences may be mediated in part by the absence of bovine milk components, or by the presence of bioactive components of human milk that promote brain growth and development, including micronutrients, such as iron and zinc (18) , neurotrophic factors, such as brain-derived neurotrophic factor and glial cell-derived neurotrophic factor (19) , and cytokines, such as transforming growth factor (TGF)-β and tumor necrosis factor (TNF)-α (20) . Many of these components are to some degree resistant to heat (21) , and presumably are present in HMBF. The HMBF also provided slightly more protein than the BMBF used in our original trial at what seems to be a sensitive period, as intakes of protein, lipid, and energy in the first weeks following birth have been associated with performance on neurodevelopmental tests at 1 y and 18 mo among infants born at a VLBW (22, 23) . Another important consideration is that the HMBF used in our study was provided in liquid form and displaced between 25-67% of other human milk (mother or donor) from the infants' diets (16) . This displacement could lead to unintended neurodevelopmental consequences that require investigation. Here, we present the results of the first randomized clinical trial of HMBF and BMBF with neurodevelopmental follow-up.
Methods
The participants with follow-up assessments reported here were enrolled in the OptiMoM (Optimizing Mothers' Milk for Preterm Infants) Fortifier Study (NCT02137473), a pragmatic, multi-center, triple-blind, parallel group, randomized clinical trial designed to compare the efficacy of using HMBF or BMBF in infants born <1250 g fed maternal milk supplemented with donor milk as necessary. The primary outcome of the OptiMoM Fortifier Study was feeding tolerance, with secondary outcomes including growth, gut inflammation, and neonatal mortality and morbidity. Participants were enrolled in the original trial between August 2014 and November 2015 from neonatal intensive care units at Sinai Health System and the Hospital for Sick Children in Toronto, Canada.
Details of the trial methods and results of the original trial have been published (16) . Briefly, infants were included if they were born <1250 g and if their parents consented to use supplemental donor milk in the absence of sufficient maternal milk. Infants were excluded if they received infant formula or a BMBF prior to randomization, if enteral feeding was not initiated within 14 d of birth, if they had a chromosomal or congenital anomaly that could affect growth, if they were participants in another study that affected their nutritional management, or if they were likely to be transferred to a neonatal intensive care unit where the study protocol could not be followed.
As part of routine care, each study participant qualified for neonatal neurodevelopmental follow-up at 18-mo corrected age (age taken from expected date of delivery). These assessments occurred between May 2016 and October 2017 at the neonatal follow-up clinics at each recruiting hospital. The protocols for both the original study and this followup were approved by the institutional Human Research Ethics Boards at Sinai Health System and the Hospital for Sick Children in Toronto, Canada. Consent was obtained from the parents or guardians of participants. Baseline characteristics for the study participants were collected from patient records and from questionnaires administered by study staff.
Feeding intervention
Full details of the feeding intervention, including the weight-based feeding protocol, have been published previously (16) . Infants were randomized by a third-party online service in blocks of 4, stratified by birth weight <1000 g or 1000-1250 g and recruitment center. Briefly, infants were fed maternal milk whenever it was available and donor milk as required; enteral feeds were prepared fresh daily under laminar flow in 1 of 2 designated milk preparation rooms. Tube feeds were prepared in amber syringes, and bottles were wrapped in colored cellophane to maintain blinding of families, healthcare providers, and study staff. Fortification began once enteral feeds reached 100 mL/kg/d, with full enteral feeding considered to be achieved at 160 mL/kg/d. In addition to the study fortifiers, infants were prescribed iron (2-3 mg/kg/d elemental) and vitamins A (375 IU), C (17.5 mg/d), and D (400 IU until body weight reached 2000 g, 200 IU thereafter). The intervention lasted until the first of the following occurred: infants were aged 84 d, were discharged from hospital, or were consistently able to consume 2 oral feeds daily.
Fortification in both groups was initiated when infants reached an enteral tolerance of 100 mL/kg/d. Feeds in the HMBF group were fortified according to the published feeding protocol (16) with Prolact + 4, Prolact + 6, and Prolact + 8 (Prolacta Bioscience City of Industry). Fortification began at 0.81 kcal/mL (2.2 g protein/100 mL prepared feed) and was increased to 0.88 kcal/mL (2.7 g protein/100 mL) when the infant reached intakes of 140 mL/kg/d. In the BMBF group, feeds were fortified with Similac Human Milk Fortifier Powder (Abbott Nutrition) and Similac Neosure powdered formula (Abbott Nutrition); both containing intact protein. Fortification began at 0.72 kcal/mL (1.7 g protein/100 mL prepared feed) and was increased to 0.78 kcal/mL (2.2 g protein/100 mL) once the infant reached intakes of 140 mL/kg/d. An intact protein module (Beneprotein, Nestle Health Sciences) was added to donor milk (0.4 g/100 mL) in the BMBF group once fortification reached 0.78 kcal/mL to better mimic the protein content of maternal milk. No additional bovine protein fortification was added to donor milk in the HMBF group. In both groups, additional fortification was provided to meet growth targets.
Study outcomes
The Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III, Pearson Education, Inc.) was offered to all participants at 18-mo corrected age. Briefly, the Bayley-III is a standardized neurodevelopmental test routinely administered to infants born at a VLBW as part of neonatal follow-up. It consists of cognitive, language (receptive, expressive), and motor (gross, fine) subtests that are converted to ageadjusted composite scores standardized to have a mean of 100 and an SD of 15. Scores can be further classified as Very Superior (≥130), Superior (120-129), High Average (110-119), Average (90-109), Low Average (80-89), Borderline (70-79), and Extremely Low (≤69). Families remained blinded to the treatment assignment and tests were administered by trained, blinded assessors, either at the neonatal follow-up clinics at Sinai Health System or the Hospital for Sick Children, or in the participants' homes if they were unable to attend a follow-up appointment. Interrater reliability between assessors was over 80% in videotaped sessions, and tests were double counted by a second researcher unaware of the feeding assignments. As with our previous study (6) and in line with other experts in the field (24, 25) , those who attended the follow-up visit but could not complete the Bayley-III due to disability or who performed below the threshold for individual composite scores were assigned a score of 49.
Data on visual impairment (acuity <20/200 despite amplification), hearing impairment (requiring amplification), or diagnosis of cerebral palsy (diagnosis by doctor blinded to treatment assignment) were collected from the medical records at the 18-mo assessment. Death and neurodevelopmental impairment or death and neurodevelopmental disability were calculated as dichotomous variables by combining infants who either died during the intervention (i.e. after receiving the first fortified feed), or were diagnosed with cerebral palsy or an impairment in hearing or vision, or who scored below cutoffs on the Bayley-III, similar to previous studies (6, 26, 27) . The Bayley-III cut-off used for neurodevelopmental impairment was <85, whereas <70 was used for the categorization of neurodevelopmental disability.
Statistical analysis
Analysis was carried out in SAS version 9.4 (SAS Institute). Infants who were randomized but who died prior to receiving either study feed (n = 2) and survivors who withdrew from the study (n = 2) or did not attend the 18-mo corrected age follow-up visit and for whom follow-up in their home could not be arranged (n = 7) were not included in the analysis (Figure 1) . Participants who died during the study (n = 7) were not included in the analysis of Bayley-III composite scores, but they were included in the analysis of the dichotomous death and neurodevelopmental impairment or neurodevelopmental disability variables. Because of the high rate of follow-up (86% of all subjects, 92% of survivors) and completeness of the dataset, we did not perform any imputation of missing data. Composite scores on the Bayley-III are standardized to a mean of 100 with an SD of 15 (28) . Thus, our sample of 109 infants with neurodevelopmental follow-up could provide 80% power at α = 0.05 to detect an 8 point difference in mean composite scores between fortifier groups. Sample size varies slightly by subtest, as a small number of participants did not complete parts of the Bayley-III [language n = 3 (1 in the HMBF group and 2 in the BMBF group), and motor n = 1 (in the HMBF group)] due to behavior. Further, 2 subjects included in the primary analysis had missing data for maternal education or income [n = 2, (both in the HMBF group)], which reduced the available sample size for the fully adjusted model 2.
Baseline characteristics were compared between the groups using chi-square tests for categorical variables, t-test for normally distributed continuous variables, and the Kruskal-Wallis test for nonnormally distributed continuous variables. Composite scores for each of the 3 Bayley-III domains were analyzed as continuous variables using linear regression models (PROC GLM) adjusting for birth weight strata (<1000 g or 1000-1249 g) in model 1, and for birth weight strata, sex, small for gestational age (y/n), any donor milk intake (y/n), maternal education (high school or less, college or vocational diploma, baccalaureate, postbaccalaureate), and income above or below the poverty line (y/n under the family size-adjusted Ontario poverty line) in model 2. The dichotomous variables of death and neurodevelopmental impairment or death and neurodevelopmental disability were analyzed using logistic regression adjusting for birth weight strata and sex. Interactions between feeding group and the covariates included in each model were tested and removed from the model if nonsignificant. All tests of significance were 2-sided with P < 0.05 after adjustment for multiple comparisons (Tukey-Kramer) considered statistically significant. Data were analyzed using superiority statistics because the substantial additional cost of feeding an infant with HMBF [estimated at >$10,000 in 2012 (29) ] and greater potential for displacement of maternal milk from infant diets (up to 67%) necessitate some evidence of benefit to justify a switch from the BMBF standard of care.
Results

Study infants
Of the 232 participants approached for the original study, 127 were randomized: 64 to receive HMBF added to maternal milk or donor milk, and 63 to receive BMBF (Figure 1) . Median duration in the study intervention was 48 d (IQR 30-61) in the HMBF group, and 51 d (39-62) in the BMBF group (P = 0.43) (16) . As reported previously, 2 infants in the BMBF group died prior to receiving their first fortified feed and were not included in the analysis of any outcomes, and an additional 2 withdrew from the original study with no further data collection (16) . Seven infants died during the original study period, 4 in the BMBF group and 3 in the HMBF group (16) . Seven survivors did not complete the 18-mo follow-up visit (2 in the HMBF group and 5 in the BMBF group) due to moving out of the study area (n = 2), lack of interest (n = 2), behavior (n = 1), or loss to follow-up (n = 2). Of the infants who received the fortifier as randomized, 59/64 (92%) of infants in the HMBF and 50/60 (83%) of infants in the BMBF groups attended the 18-mo corrected age visit and had neurodevelopment assessed (P = 0.79).
Eligible infants (n = 232)
Excluded (n = 105) Not interested (n = 70) Prefers standard clinical pracƟce (n = 30) Unknown (n = 5) Randomized (n = 127)
Received feeding intervenƟon as randomized (n = 64)
Received feeding intervenƟon as randomized (n = 60) Died prior to study day 1 (n = 2) Received HMBF, withdrew (n = 1)
Human milk-based forƟfier (HMBF, n = 64) Bovine milk-based forƟfier (BMBF, n = 63)
Included in composite of death and neurodevelopmental impairment (n = 62)
Died aŌer study day 1 (n = 3) Neurodevelopment assessed (n = 59)
Included in composite of death and neurodevelopmental impairment (n = 54)
Died aŌer study day 1 (n = 4) Neurodevelopment assessed (n = 50) 
Neurodevelopment
Neurodevelopment was assessed in 109 of the 118 surviving participants, a response rate of 92%. There were no significant differences in baseline characteristics of the children who attended the 18-mo neurodevelopmental follow-up between the 2 fortifier groups ( Table 1 ). Infants were born at a mean of 897 g (SD 201 g) and 27.8 (SD 2.5) weeks of gestation; 62.4% of infants were born weighing <1000 g and 23.9% were classified as small for gestational age. Females accounted for 57.8% of the study population. There were few differences in baseline characteristics between participants who did and did not complete the 18-mo neurodevelopmental follow-up (Supplemental Table 1 ). No significant differences in mean cognitive, language, or motor composite scores were identified between the treatment groups, either in the base or fully adjusted models ( Table 2) . For model 1, adjusted only for birth weight strata (<1000 g or 1000-1249 g), the adjusted mean cognitive composite scores were 94.7 in the HMBF group compared with 95.9 in the BMBF group, an adjusted mean difference of −1.2 (95% CI: −6.7 to 4.4). Comparing the HMBF and BMBF groups, adjusted mean composite scores were 92.4 versus 93.1 [mean difference −0.7 (−7.4 to 6.1)] for language and 95.6 versus 97.7 [mean difference −2.1 (−7.3 to 3.1)] for motor subtests. The mean differences between the HMBF and BMBF groups in model 2, adjusted for birth weight strata, sex, small for gestational age, maternal education, income above or below the family size-adjusted poverty line, and donor milk intake, were −1.1 (−6.5 to 4.4) for cognition, −1.2 (−7.5 to 5.1) for language, and −1.1 (−6.3 to 4.2) for motor scores. Results were unchanged when an additional model was run including a major in-hospital morbidity composite (late-onset sepsis, chronic lung disease, NEC, or retinopathy of prematurity requiring treatment) and a composite social risk score [adapted from a previously published method (30) including family structure (single or dual parent household), maternal education (less than university educated or university and above), language spoken at home (no English or English), maternal age (under or over 21), and income (below or above the family size-adjusted poverty line)] (data not shown). Findings were also unchanged in sensitivity analyses excluding infants with cerebral palsy (n = 4), a hearing impairment (n = 2), or brain injury (n = 14) (Supplemental Table 2 ). None of the participants were diagnosed with a visual impairment. Similarly, results were unchanged in sensitivity analyses where participants enrolled at the Hospital for Sick Children (n = 16) were excluded (Supplemental Table 3 ), or when participants who were assigned scores of 49 were excluded for each of the cognitive, language, and motor composite analyses (Supplemental Table 4 ).
Proportions of children were also compared for a dichotomous outcome of death and neurodevelopmental impairment (scores <85) or death and neurodevelopmental disability (scores <70) ( Table 3) . No statistically significant differences were identified between the fortifier groups for any subtest in either an unadjusted model or a model adjusting for birth weight strata and sex. For the cognitive domain, 24.2% and 22.2% children died or had impaired neurodevelopment in the HMBF and BMBF groups, respectively. For language, the proportions were 36.1% with death or neurodevelopmental impairment in the HMBF group and 40.4% of those in the BMBF group, whereas in the motor domain, 23.0% of those in the HMBF group and 22.2% of those in the BMBF group died or were classified as having a neurodevelopmental impairment. No statistically significant differences were found between groups with respect to the proportion of children who died or had a neurodevelopmental disability for any domain. Similar results were obtained when the analysis was run only for composite scores <85 or <70 excluding those who died, had cerebral palsy, or had an impairment in vision or hearing (Supplemental Table 5 ), though reliability is limited by the small sample size.
Discussion
In this follow-up study, no neurodevelopmental advantage was identified to providing infants born <1250 g a HMBF rather than a BMBF on top of a human milk background diet which consisted of maternal milk when available and supplemental pasteurized donor milk. Specifically, no statistically significant differences were identified in cognitive, language, or motor composite scores on the Bayley-III between the groups in either unadjusted or adjusted statistical models. The fully adjusted mean differences in composite scores between HMBF and BMBF range between −1.1 and −1.2 (favoring BMBF) with all CIs including 0. This is less than the minimal clinically important difference of 5 points that has been used previously for the Bayley-III in VLBW infants (6, 31) . Thus, although not superior to BMBF, the HMBF is also not inferior with respect to neurodevelopment as assessed by the Bayley-III. There were also no significant differences in the proportions of participants who died or had a neurodevelopmental disability or neurodevelopmental impairment between the 2 groups. These results were unchanged in sensitivity analyses in which children with brain injury, hearing impairment, or cerebral palsy were excluded. Thus, the nutritional and bioactive component differences that arose in the 2 arms of the study as a result of differences in the nutrient composition of the HMBF and BMBF, including amount of supplemental donor milk required and displacement of maternal milk, may be insufficient to influence neurodevelopment at 18-mo corrected age among children born <1250 g. The present study is the first randomized clinical trial to compare neurodevelopment in infants fed a BMBF or a HMBF; however, 1 previous paper addressed this point with a retrospective chart review (32) that compared performance on the Bayley-III at 6-, 12-, and 18-mo corrected age in infants born before or after a hospital introduced the use of a HMBF for infants born <1000 g and <37 weeks gestational age. Infants born prior to the introduction of this program received ma-ternal milk fortified with BMBF and infant formula as a supplement in the absence of sufficient maternal milk, whereas infants born after the introduction of the program received only human milk products, including maternal milk fortified with HMBF and donor milk (without additional protein fortification as was provided in our study) when the maternal milk supply was insufficient, for ≥4 wk and until a weight >1500 g or a postmenstrual age of ≥34 wk was reached. Similar to our study, they identified no differences between the groups in any Bayley domain or in the proportions of infants with neurodevelopmental disability. Because the groups in this study differed both in the type of fortifier they received and in the feeding of supplemental infant formula or donor milk, no firm conclusions on the use of HMBF or BMBF could be drawn. By maintaining all infants on a human milk diet of maternal milk supplemented with donor milk when necessary, our study is the first to directly compare the effects of HMBF and BMBF on neurodevelopment.
Two previous trials reported improvements in feeding tolerance and lower rates of NEC in VLBW infants fed maternal milk with supplemental donor milk and a HMBF compared with those fed maternal milk with bovine milk products, including supplemental infant formula, and BMBF (10) (11) (12) . This is relevant to the present analysis because early-life morbidity or suboptimal growth can translate into neurodevelopmental delays later in life (33, 34) . As with the above-mentioned retrospective Our findings with respect to neurodevelopment reported herein are consistent with these earlier findings. Future studies are needed to determine whether there are any long-term effects of fortifier type on eye health. The strengths of this article include the randomized design, use of a consistent human milk diet between the treatment groups, a high rate of follow-up, and a population representing a range of ethnicities and income levels. This is the first study to compare the neurodevelopmental effects of feeding HMBF or BMBF on a diet containing only human milk without any infant formula, which is the current standard of care in North America (13, 14) . Thus, these findings are extremely relevant to hospitals and care providers evaluating the adoption of HMBF as opposed to BMBF, especially given the additional financial cost of providing HMBF.
A limitation of the neurodevelopment analyses reported here is that the sample size was established to estimate treatment differences in in-hospital feeding tolerance, and not scores on the Bayley-III. A posthoc power calculation of the cognitive, language, and motor composites suggest we were powered (80%, α-level of 0.05) to detect a 0.48-0.55 SD difference or 7-9.5 point difference between treatment groups. Although a 0.5 SD difference is generally considered a moderate effect size in psychological research (35) , including in previous studies using the Bayley-III in children born preterm or at a VLBW (36) (37) (38) , it is greater than the minimal clinically important difference of 5 points we and others have used previously (6, 31) . This being said, in the present analyses, the mean differences in composite scores were generally 2 points or less, which is unlikely to be clinically relevant. A further limitation of this work is that scores on the Bayley-III at 18-mo corrected age may not be predictive of other important neurodevelopmental outcomes, such as performance at school age or IQ, particularly in studies with nutritional interventions (3, 39) . Future studies that use more sensitive measurements and/or later time points would be useful for the further evaluation of the use of HMBF.
In conclusion, we identified no neurodevelopmental benefit or detriment at 18-mo corrected age of feeding a HMBF compared with a BMBF during initial hospitalization in infants born at <1250 g. In infants being fed a human milk diet (maternal milk supplemented with donor milk where necessary), the evidence does not support use of HMBF rather than BMBF for improved neurodevelopment.
